Nucleic Acid Therapeutics is the leading journal in its field focusing on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. The Journal examines many new approaches for using nucleic acids as therapeutic agents or in modifying nucleic acids for therapeutic purposes including: oligonucleotides, gene modification, aptamers, RNA nanoparticles, and ribozymes.

Nucleic Acid Therapeutics coverage includes:

• RNAi: siRNAs, shRNAs, and miRNAs
• Antisense applications; nucleoside and nucleotide analogs and modifications
• Peptide nucleic acids
• DNA-modified gene therapy
• Nucleic acid-based nanoparticles
• Ethical, legal, and regulatory issues

Nucleic Acid Therapeutics is under the editorial leadership of Editor-in-Chief Bruce A. Sullenger, PhD,Duke Translational Research Institute, Duke University Medical Center; Executive Editor Graham C. Parker, PhD; and other leading investigators. View the entire editorial board.

Audience: Molecular biologists, biochemists, DNA and cell biologists, and biopharmaceutical researchers, among others.

Nucleic Acid Therapeutics is a rapid-publication Journal, with peer review averaging 25 days from submission to first decision, and online publication of the article within four weeks of acceptance.